Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.88 USD | +8.11% | -0.98% | +72.55% |
May. 06 | Oppenheimer Upgrades Chemomab Therapeutics to Outperform | MT |
Apr. 10 | Transcript : Chemomab Therapeutics Ltd. - Special Call |
Chart calendar Chemomab Therapeutics Ltd.
Upcoming events on Chemomab Therapeutics Ltd.
Past events on Chemomab Therapeutics Ltd.
2024-05-09 07:00 am | Q1 2024 Earnings Release |
2024-05-07 09:00 am | Aegis Capital Virtual Conference |
2024-04-10 10:00 am | Investor Meeting - Key Opinion Leader |
2024-03-12 10:40 am | Leerink Partners Global BioPharma Conference |
2024-03-07 07:00 am | Q4 2023 Earnings Release |
2024-02-14 08:00 am | Oppenheimer Healthcare Life Sciences Conference |
2023-11-15 | American College of Rheumatology Convergence |
2023-11-14 12:00 pm | American College of Rheumatology Conference |
2023-11-13 04:30 pm | AASLD Liver Meeting |
2023-11-11 01:00 pm | AASLD Liver Meeting |
2023-11-09 08:00 am | Q3 2023 Earnings Release |
2023-10-12 12:00 pm | Roth Healtcare Opportunities Conference |
2023-09-11 07:00 am | H.C. Wainwright Global Investment Conference |
2023-08-14 08:00 am | Q2 2023 Earnings Release |
2023-06-23 03:00 am | European Association for the Study of the Liver Congress - Abstract No. #2178 |
2023-06-22 03:00 am | European Association for the Study of the Liver Congress |
2023-06-21 03:00 am | European Association for the Study of the Liver Congress - Poster No. -Late-Breaker, LBP-28 |
2023-06-04 | BIO International Convention |
2023-06-02 08:45 am | EULAR Congress |
2023-05-12 11:20 am | EASL Monothematic Conference |
Annual results
Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
EBITDA | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
EBIT Million USD | Released Forecast Spread | 0,00 | -12,4 -10,8 -14.92% | -28,5 -28,6 0.39% | -25,5 -26,0 1.97% | -16,0 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -12,5 -10,8 -15.31% | -28,2 -28,6 1.63% | -24,2 -25,0 3% | -15,8 |
Net income Million USD | Released Forecast Spread | -5,95 | -12,5 -10,8 -15.31% | -27,6 -28,4 2.64% | -24,2 -25,1 3.36% | -15,9 |
EPS USD | Released Forecast Spread | 0,00 | -0,06 -0,04 -50% | -0,12 -0,12 -5.22% | -0,10 -0,11 6.36% | -0,05 |
Announcement Date | 19/03/21 | 09/03/22 | 21/02/23 | 07/03/24 | - |
Quarterly results
Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 |
EBIT Million USD | Released Forecast Spread | -5,02 -3,43 -46.34% | -5,32 -5,17 -2.87% | -6,25 -5,76 -8.59% | -8,32 -6,52 -27.49% | -8,64 -8,75 1.23% | -9,05 -9,40 3.73% | -8,20 -9,10 9.95% | -4,37 -5,00 12.66% | -3,85 -4,36 11.72% | -3,88 | -3,99 | -4,03 | -4,06 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -5,04 -3,78 -33.4% | -5,10 -5,50 7.2% | -6,73 -5,75 -17.11% | -8,08 -6,40 -26.25% | -8,26 -8,75 5.58% | -8,73 -9,40 7.11% | -7,94 -8,83 10.07% | -4,14 -4,75 12.93% | -3,42 -4,17 18% | -3,85 | -4,05 | -4,05 | |
Net income Million USD | Released Forecast Spread | -5,04 -3,40 -48.07% | -5,10 -5,41 5.72% | -6,19 -5,69 -8.86% | -8,08 -6,69 -20.84% | -8,27 -8,75 5.46% | -8,75 -9,40 6.88% | -7,97 -8,83 9.69% | -4,08 -4,75 14.08% | -3,42 -4,26 19.77% | -3,88 | -3,89 | -4,03 | -4,06 |
EPS USD | Released Forecast Spread | -0,02 -0,02 -10% | -0,02 -0,25 91.02% | -0,03 -0,18 85% | -0,04 -0,23 84.78% | -0,04 -0,03 -20% | -0,04 -0,04 -14.29% | -0,04 -0,04 10% | -0,02 -0,02 15% | -0,01 -0,02 35% | -0,02 | -0,02 | -0,01 | -0,01 |
Announcement Date | 09/03/22 | 12/05/22 | 12/08/22 | 10/11/22 | 21/02/23 | 11/05/23 | 14/08/23 | 09/11/23 | 07/03/24 | - | - | - | - |
2024-05-15 | BIOCON LIMITED: Q4 2024 Earnings Release |
2024-05-16 09:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
2024-07-23 | VIKING THERAPEUTICS, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-24 | BIOCON LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-25 01:00 am | ARGENX SE: Q2 2024 Earnings Release |
2024-07-29 | RHYTHM PHARMACEUTICALS, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-29 | NEUROCRINE BIOSCIENCES, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-29 | CEREVEL THERAPEUTICS HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-30 | CASSAVA SCIENCES, INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for Chemomab Therapeutics Ltd.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CMMB Stock
- Calendar Chemomab Therapeutics Ltd.